Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 987
countries
28
conditions
2 109

8 trials match your criteria

Respiratory syncytial virus infection

Recruiting

Study of RSV vaccine and nirsevimab combination to prevent RSV infection in infants up to 12 months of age

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Nirsevimab

Bronchiolitis+1

Recruiting

Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nirsevimab

Allogenic stem cell transplantation

Recruiting

Study on RSV Vaccination with Abrysvo and Arexvy for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E

Respiratory syncytial virus immunisation

Not yet recruiting

Safety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A

Respiratory syncytial virus infection

Not yet recruiting

Effectiveness of a second dose of RSV subgroup A 847A and subgroup B 847B versus primary dose to prevent respiratory syncytial virus infection in immunocompromised adults

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A

Allogenic stem cell transplantation+1

Not yet recruiting

Immunogenicity and safety of RSV A/B prefusion F protein vaccine versus RSV F glycoprotein recombinant adjuvanted vaccine in lung and stem cell transplant recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E

Systemic lupus erythematosus+6

Not yet recruiting

Study of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E

Respiratory syncytial virus infection

Not recruiting

Study on the Effectiveness of RSV Vaccine (Abrysvo) in Preventing Hospitalizations in Adults Aged 60 and Older

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.